Free previewYou're reading the free part of this topic. The rest is included with Clinical.See what's included
Corneal Graft Rejection
Cornea
1. Clinical Analogy & Conceptual Overview
THE BOUNCER ANALOGY
- Imagine the cornea as a VIP lounge that operates without bouncers (immune privilege). The donor graft is a new celebrity that has just entered. Initially, the host's immune system does not recognize the stranger - the lounge is 'antigen-ignorant.' But once the host's immune surveillance is breached - via new blood vessels growing in (neovascularization = hiring bouncers), or via direct sensitization - the host's T-cells and antibodies storm in and start attacking the graft endothelium. The result: corneal edema, Descemet's folds, and eventual graft failure. Every therapeutic maneuver in rejection is aimed at kicking the bouncers out before they destroy the lounge.
Conceptual Definition
- Corneal graft rejection (allograft rejection) is an immunologically mediated destruction of donor corneal cells by the recipient's immune system.
- It is the leading cause of graft failure in penetrating keratoplasty.
- Rejection occurs in approximately 16% of primary penetrating keratoplasties in one 20-year cohort; 30–60% of high-risk penetrating keratoplasty grafts may have rejection episodes, and up to 70% may fail within 10 years.
Key Distinguishing Concept: Rejection vs. Failure
| Feature | Rejection | Primary Graft Failure |
|---|---|---|
| Timing | • Weeks to years post-op | • Immediate post-op |
| Mechanism | • Immune mediated | • Surgical/donor endothelial damage |
| Reversibility | • Potentially reversible if caught early | • Irreversible |
| Khodadoust line | • May be present, especially in endothelial rejection | • Absent in primary graft failure |
| Prior clarity | • Graft was clear initially | • Never became clear |
| Feature | Rejection | Primary Graft Failure |
|---|---|---|
| Timing | • Weeks to years post-op | • Immediate post-op |
| Mechanism | • Immune mediated | • Surgical/donor endothelial damage |
| Reversibility | • Potentially reversible if caught early | • Irreversible |
| Khodadoust line | • May be present, especially in endothelial rejection | • Absent in primary graft failure |
| Prior clarity | • Graft was clear initially | • Never became clear |
2. Immunology of Corneal Immune Privilege
Why Does the Cornea Enjoy Immune Privilege?
- The cornea is the most successfully transplanted tissue in the body (>40,000 grafts/year in the United States).
- This success is due to immune privilege - a property shared with the anterior chamber, vitreous, testis, and brain.
- Understanding its mechanisms is key to understanding rejection.
Mechanisms of Corneal Immune Privilege
- Avascularity and alymphaticity: Blood and lymphatic vessels are absent from the normal cornea, limiting and delaying antigen trafficking to regional lymph nodes and reducing sensitization risk.
- Anterior Chamber-Associated Immune Deviation (ACAID): Antigens entering the anterior chamber induce antigen-specific systemic tolerance via transforming growth factor beta 2 (TGF-β2), regulatory T cells (Tregs), and natural killer T cells (NKT cells).
- Fas ligand (FasL; cluster of differentiation 95 ligand [CD95L]) expression: Corneal cells express Fas ligand (FasL; cluster of differentiation 95 ligand [CD95L]) and induce apoptosis in infiltrating Fas-positive T lymphocytes.
- Programmed death ligand 1 (PD-L1) expression on corneal cells suppresses T-cell activation.
- Complement regulatory proteins: Cluster of differentiation 55 (CD55; decay-accelerating factor), cluster of differentiation 59 (CD59), and cluster of differentiation 46 (CD46) protect against complement-mediated lysis.
- Transforming growth factor beta 2 (TGF-β2)-rich aqueous humor: Suppresses natural killer cells (NK cells) and macrophages; together with alpha-melanocyte-stimulating hormone (α-MSH), promotes regulatory T-cell differentiation.
- Human leukocyte antigen (HLA) expression pattern: Low major histocompatibility complex class I (MHC class I) and absent major histocompatibility complex class II (MHC class II) on stromal keratocytes reduce allorecognition.
- Neuropeptides: Alpha-melanocyte-stimulating hormone (α-MSH), vasoactive intestinal peptide (VIP), and calcitonin gene-related peptide (CGRP) in aqueous humor suppress immune activation.
When Immune Privilege Breaks Down - The Tipping Point
| Privilege Factor | Normal State | After Breakdown |
|---|---|---|
| Vascularity | • Avascular | • Neovascularization → antigen trafficking |
| Donor human leukocyte antigen (HLA) match | • Not routinely required in low-risk corneal transplantation | • Mismatch alone does not inevitably drive sensitization • Inflammatory, vascularized, or otherwise high-risk graft beds increase alloimmune risk |
| Langerhans cells | • Absent from central cornea | • Migrate centrally post-surgery |
| Anterior chamber-associated immune deviation (ACAID) | • Active, antigen-specific systemic tolerance | • Inflammation and high-risk ocular conditions can impair or abolish this tolerogenic response |
| Lymphatics | • Absent | • Lymphangiogenesis (vascular endothelial growth factor C/D [VEGF-C/D] mediated) |
| Privilege Factor | Normal State | After Breakdown |
|---|---|---|
| Vascularity | • Avascular | • Neovascularization → antigen trafficking |
| Donor human leukocyte antigen (HLA) match | • Not routinely required in low-risk corneal transplantation | • Mismatch alone does not inevitably drive sensitization • Inflammatory, vascularized, or otherwise high-risk graft beds increase alloimmune risk |
| Langerhans cells | • Absent from central cornea | • Migrate centrally post-surgery |
| Anterior chamber-associated immune deviation (ACAID) | • Active, antigen-specific systemic tolerance | • Inflammation and high-risk ocular conditions can impair or abolish this tolerogenic response |
| Lymphatics | • Absent | • Lymphangiogenesis (vascular endothelial growth factor C/D [VEGF-C/D] mediated) |
VIVA PEARL
- Anterior chamber-associated immune deviation (ACAID) is an important mechanism of ocular immune privilege.
- The splenic pathway involves F4/80-positive macrophages, natural killer T cells, and regulatory T cells.
- Uveitis disrupts the blood–ocular barrier and is a risk factor for corneal graft rejection.
- Herpes simplex virus (HSV) keratitis can abolish ocular immune privilege and is a major risk factor for corneal graft rejection.
- Glaucoma, particularly pre-existing glaucoma, is a risk factor for corneal graft failure. Elevated intraocular pressure can contribute to graft damage.
- Transforming growth factor beta 2 in aqueous humor contributes to ocular immune privilege together with cortisol and other immunosuppressive factors.
Free preview ends here
Keep reading Corneal Graft Rejection
15 more sections are included with the Clinical plan.
- Pathophysiology of Graft Rejection
- Types of Corneal Graft Rejection
- Clinical Features - Endothelial Rejection
- Khodadoust Line - The Pathognomonic Sign
- Risk Factors for Rejection
- Investigations